Abivax Shares Approach Critical Technical Juncture

Abivax shares test technical support as investors await Phase 3 results in Q2 2026 and March 2025 financials detailing cash runway through 2027.

Following a recent sell-off, Abivax shares are nearing a pivotal chart-based support level. As short-term momentum weakens, investor attention is shifting to upcoming fundamental catalysts and the company's financial runway. The key question for the market is whether impending clinical trial data can catalyze a reversal.

Financial Milestones and Cash Position in Focus

Two near-term dates are fundamental to the investment thesis. The company is scheduled to release its full-year 2025 financial results on March 23. Scrutiny will center on the cash burn rate, though management has previously stated that operational funding is secured through the fourth quarter of 2027.

The most significant operational catalyst is expected by the end of the second quarter of 2026. At that time, Abivax anticipates reporting the topline results from the Phase 3 maintenance study (ABTECT) for its drug candidate, obefazimod. This data is a mandatory prerequisite for the planned regulatory submissions to the FDA and EMA, which the company targets for the second half of 2026. The March 23 financial update will provide the market with fresh details on the firm's fiscal stability ahead of these events.

Key Chart Levels Under Scrutiny

The stock's decline of nearly five percent this past Friday brought its price to €93.70. This move positions the equity close to a critical technical area. Immediate support is seen at €93.35, which marks the lower boundary of the Bollinger Bands—a level often monitored by traders for potential price stabilization.

Further context is provided by the Relative Strength Index (RSI). Currently reading 37, the indicator shows the stock has moved near oversold territory following recent declines, suggesting the correction has been intense.

Long-Term Trend Remains Intact Despite Short-Term Weakness

The current phase of weakness has created significant distance from key short- and medium-term trend indicators. Both the 20-day moving average at €103.79 and the 50-day moving average at €104.73 sit well above the current trading price. As long as the share price remains below these levels, short-term momentum is considered negative.

However, the broader technical picture remains constructive. The 200-day moving average (GD200) sits at approximately €70.48. This means the stock continues to trade substantially above its long-term trend, framing the recent pullback as a consolidation within a broader upward trajectory.